AGIO Quote, Trading Chart, Agios Pharmaceuticals Inc.

$61.27 Last:

1.34% Change Percent:

$60.4 Open:

$61.27 Previous Close:

$62.155 High:

$59.75 Low:

712,407 Volume:

06/21/2021 04:42:36 am Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Stock Date	Open Price	Close Price	High	Low	Volume
2021-06-21	60.4	61.27	62.155	59.75	712,407
2021-06-18	59.41	60.46	60.83	59.08	1,526,868
2021-06-17	58.58	59.75	60.1	58.45	488,249
2021-06-16	58.24	58.78	59.205	58.05	391,603
2021-06-15	56.82	58.18	58.35	56.82	405,015
2021-06-14	57.46	58.24	58.47	57.46	521,108
2021-06-11	59.84	57.74	59.84	56.88	561,805
2021-06-10	60.06	59.5	60.335	59.19	586,318
2021-06-09	60.05	58.9	60.71	58.62	369,873
2021-06-08	59.6	59.98	60.16	58.11	277,824
2021-06-07	57.67	59.65	60.13	57.6	636,547
2021-06-04	57.5	57.6	58.18	56.79	368,099
2021-06-03	56.46	57.13	57.36	56.13	236,509
2021-06-02	56.17	56.56	56.7	55.77	311,382
2021-06-01	55.68	55.87	56.59	55.47	718,972
2021-05-31	57.29	55.78	58.13	55.68	318,085
2021-05-28	57.29	55.78	58.13	55.68	317,479
2021-05-27	56.37	57.1	57.12	55.73	340,538
2021-05-26	56.36	56.31	56.55	55.93	282,944
2021-05-25	56.57	55.86	57.215	55.84	539,945

Stock Information

Agios Pharmaceuticals Inc. Company Name:

AGIO Stock Symbol:

NASDAQ Market:

Get AGIO Alerts

News, Short Squeeze, Breakout and More Instantly...

AGIO - Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that it has submitted a New Drug Application (NDA) f...
AGIO - Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress

– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021 – – Agios to Host Investor Webcast Today at 7:30 a.m. ET – CAMBRIDGE, Mas...
AGIO - Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent ?- and ?-Thalassemia at the European Hematology Association Virtual Congress

– Study Met Primary Endpoint; Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 16 of 20 (80%) Patients During Weeks 4-12 – – Mitapivat Safety Profile Consistent with Previously Published Studies – – Agios to H...